Estados Unidos · Plataformas y datos · MarketBeat

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path

Publicado por MarketBeat · Estados Unidos hace 1 h

WAVE Life Sciences (NASDAQ:WVE) outlined progress across its obesity-focused siRNA program and RNA editing pipeline during a Chardan discussion, with President and CEO Paul Bolno…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path

También te puede interesar

My father-in-law, 81, sold his $75,000 home and paid off his daughter’s $50,000 debt. What happens to him now?

Tesla Asian supplier shares fall after mixed Q3 earnings, cautious outlook

IBM Stock Heads For Best Week Since June: CEO Says ‘Q2 Softness Was Timing Rather Than Demand’ After Q3 Beat, Sees Infrastructure Momentum

How Investors Are Reacting To Aya Gold & Silver Stock After Boumadine PEA Update

KFC rolls out 13 days of Halloween deals, but there’s a catch

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path

Compartir

También te puede interesar

My father-in-law, 81, sold his $75,000 home and paid off his daughter’s $50,000 debt. What happens to him now?

Tesla Asian supplier shares fall after mixed Q3 earnings, cautious outlook

IBM Stock Heads For Best Week Since June: CEO Says ‘Q2 Softness Was Timing Rather Than Demand’ After Q3 Beat, Sees Infrastructure Momentum

How Investors Are Reacting To Aya Gold & Silver Stock After Boumadine PEA Update

KFC rolls out 13 days of Halloween deals, but there’s a catch

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge